Chris Viehbacher, Managing Partner of Gurnet Point Capital, leads a $2 billion healthcare fund that invests across all. See sector focus and contact routes.
Chris Viehbacher, Managing Partner of Gurnet Point Capital, leads a $2 billion healthcare fund that invests across all stages from venture innovations to growth buyouts, with check sizes ranging from $500K to over $1B. The firm focuses on biotechnology, pharmaceuticals, medical devices, and diagnostics, targeting de-risked companies developing innovative therapies for unmet medical needs. Notable portfolio companies include Biohaven Pharmaceuticals, Corvidia Therapeutics, and Boston Pharmaceuticals, which received a $600M initial commitment to develop phase III-ready assets. Viehbacher’s distinctive thesis emphasizes being proactive “business builders” rather than passive syndicate investors, prioritizing assets with validated mechanisms and clear commercial potential.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Cambridge when building a target list.
Investors like Chris Viehbacher · Full investor directory · Investor access · Company funding database